In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

First set out in a scientific paper last September, Pathway’s post-transformer architecture, BDH (Dragon hatchling), gives LLMs native reasoning powers with intrinsic memory mechanisms that support ...

A new Bill Lawrence comedy starring Steve Carell and a new mystery starring Nicole Kidman are among this month’s highlights. By Noel Murray Some of the best shows on the streaming giant right now ...

The worlds of professional sports and entrepreneurship are colliding this summer in Park City, Utah, where elite NFL athletes will meet with proven operators and vetted founders for three days of deal ...

How does the cell convert DNA into working proteins? The process of translation can be seen as the decoding of instructions for making proteins, involving mRNA in transcription as well as tRNA. But ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...

Invest in diverse assets to build long-term wealth and gain financial freedom. Identify your investing style, budget, and risk tolerance to tailor your investment approach. Utilize passive assets like ...

To own Recursion, you have to believe its AI driven platform can turn early clinical assets and pharma collaborations into durable, less partnership dependent revenue, while managing heavy cash burn.

The editorial heaps on the fear and rolls back the clock to Vietnam War hysteria.